Navigation Links
Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
Date:12/7/2010

ALEXANDRIA, Va., Dec. 7, 2010 /PRNewswire/ -- Oxford Finance Corporation (Oxford), a subsidiary of Sumitomo Corporation, is pleased to announce the addition of Debbie Baker to its Business Development group. As director, Business Development, she is responsible for originating loan facilities for life science and medical device companies, primarily in western North America.

Ms. Baker has over 30 years of financial experience, predominantly with the healthcare industry. She has held numerous executive-level positions, including executive vice president for Capital Advisors Group, providing investment management services primarily to public and private life science and medical device companies. She also held positions as regional business development director for Questpoint, treasurer for MFS Intelenet, assistant treasurer at ASK Computer Systems, vice president of Corporate Finance and Debt for Sierra Capital Companies and treasurer for Consolidated Capital, which operated five publicly traded REITS and 22 real estate limited partnerships.

"We are extremely pleased Ms. Baker has joined Oxford's business development team," said Christopher A. Herr, managing director for Oxford Finance Corporation. "Our company and clients will benefit from her years of experience and in-depth understanding of the financial needs facing healthcare companies. Although she will be responsible for business development throughout North America, Ms. Baker will focus on serving the Bay Area and Pacific Northwest."

About Oxford Finance Corporation

A subsidiary of Sumitomo Corporation, Oxford is a specialty finance firm that provides senior secured loans to public and private life science and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $1.5 billion in loans, with lines of credit ranging from $500 thousand to $40 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Massachusetts and North Carolina. For more information visit www.oxfordfinance.com.


'/>"/>
SOURCE Oxford Finance Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
2. Oxford Finance Corporation Closes $25 Million Credit Facility with EUSA Pharma
3. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
4. Oxford Finance Corporation and United Orthopedic Group, Inc. Close $20 Million Credit Facility
5. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
6. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
7. Marc J. Fagel of the U.S. Securities and Exchange Commission to Discuss SEC Enforcement at CBIs Biotech/Pharma Finance and Accounting Forum in San Francisco
8. PhRMA Statement on Senate Finance Committee Vote
9. Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
10. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
11. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a ... commercialization of innovative therapies for the treatment of ... Agency (EMA) has notified the company that the ... Application (MAA) has passed validation, and that the ... MAA for ARX-04 (known as DSUVIA™ in the ...
(Date:3/28/2017)... MARLBOROUGH, Mass. , March 28, 2017 /PRNewswire/ ... RNAi company developing innovative therapeutics that address significant ... granted a patent from the Japan Patent Office ... targeting connective tissue growth factor (CTGF) for the ... not limited to skin fibrosis and proliferative retinopathy ...
(Date:3/28/2017)... 28, 2017 The global ... 8.0 billion by 2025, according to a new study ... infectious diseases and cancer is expected to upsurge the ... over the coming years. In addition, higher number of ... allogenic stem cell therapy, due to adverse effects caused ...
Breaking Medicine Technology:
(Date:3/28/2017)... CT (PRWEB) , ... March 28, 2017 , ... ... devices, announces today that the University of Pittsburgh Medical Center (UPMC) will acquire ... and Western Pennsylvania. , The program, developed in association with efforts by the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 dermatologists in the ... care can be limited while the desire to conquer breakouts and eliminate skincare stress ... for every customer online, today released its inaugural survey on the State of Acne ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly ... professionals in the country to sit on the 2017 National Advisory Board for Allergan’s ... years Dr. Harper helped propel the clinic from a small start-up to number 78 ...
(Date:3/28/2017)... PA (PRWEB) , ... March 28, 2017 , ... Public ... and across a variety of business channels. , While many results are clear, ... any public relations program. , When it comes to measurement, firms should always ...
Breaking Medicine News(10 mins):